BLCO
Bausch + Lomb Corporation NYSE Listed May 6, 2022$14.93
+0.40%
vs $14.87
Mkt Cap $5.3B
52w Low $11.73
46.6% of range
52w High $18.60
50d MA $15.82
200d MA $16.14
P/E (TTM)
-24.1x
EV/EBITDA
15.5x
P/B
0.8x
Debt/Equity
0.8x
ROE
-3.4%
P/FCF
-80.0x
RSI (14)
41.70
ATR (14)
$0.38
Beta
0.65
50d MA
$15.82
200d MA
$16.14
Avg Volume
477.8K
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
520 Applewood Crescent · Vaughan, ON L4K 4B4 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | 0.06 | 0.08 | +33.3% | 15.72 | +2.2% | -2.4% | +3.7% | +2.6% | -0.1% | -1.8% | — |
| Feb 18, 2026 | BMO | 0.35 | 0.32 | -8.6% | 17.73 | -5.5% | -0.3% | -0.1% | +1.6% | +0.3% | +2.5% | — |
| Oct 29, 2025 | BMO | 0.16 | 0.18 | +12.5% | 15.20 | +5.2% | +1.8% | -2.1% | -1.3% | +2.1% | -1.6% | — |
| Jul 30, 2025 | BMO | 0.06 | 0.07 | +16.7% | 14.65 | +2.9% | -6.4% | -0.6% | -1.0% | +1.6% | +5.2% | — |
| Apr 30, 2025 | BMO | 0.03 | -0.07 | -333.3% | 13.72 | -14.7% | -15.7% | +0.3% | -0.8% | -1.1% | -4.1% | — |
| Feb 19, 2025 | BMO | 0.24 | 0.25 | +4.2% | 16.35 | -0.6% | -0.3% | -2.5% | -0.9% | +0.4% | +1.0% | — |
| Oct 30, 2024 | BMO | 0.16 | 0.17 | +6.2% | 20.76 | -0.5% | -1.5% | -0.8% | +1.1% | -3.1% | -0.3% | — |
| Jul 31, 2024 | BMO | 0.13 | 0.13 | +0.0% | 16.87 | -1.8% | +2.1% | -2.1% | -3.1% | -5.7% | +3.5% | — |
| May 1, 2024 | BMO | 0.09 | 0.07 | -22.2% | 14.54 | -3.1% | -5.5% | +0.9% | -1.9% | +6.2% | +3.2% | — |
| Feb 21, 2024 | BMO | 0.17 | 0.24 | +41.2% | 14.59 | +9.3% | +13.8% | +4.3% | +1.6% | -4.1% | +1.4% | — |
| Nov 1, 2023 | BMO | 0.18 | 0.22 | +22.2% | 16.14 | +1.1% | +2.4% | +2.2% | +1.5% | -3.1% | +0.2% | — |
| Aug 2, 2023 | BMO | 0.16 | 0.18 | +12.5% | 19.35 | -0.9% | -2.3% | -0.2% | -1.3% | +0.3% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Evercore ISI | Maintains | In Line → In Line | — | $15.34 | $15.32 | -0.1% | +3.7% | +2.6% | -0.1% | -1.8% | +0.0% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $16.49 | $16.54 | +0.3% | -0.9% | -2.6% | +3.9% | -0.4% | +0.1% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.94 | $18.06 | +0.7% | +0.3% | +2.5% | +0.9% | -0.6% | -1.0% |
| Feb 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.6% | +0.3% | +2.5% | +0.9% |
| Feb 19 | Stifel | Maintains | Hold → Hold | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.6% | +0.3% | +2.5% | +0.9% |
| Feb 19 | Barclays | Maintains | Equal Weight → Equal Weight | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.6% | +0.3% | +2.5% | +0.9% |
| Feb 19 | Citigroup | Maintains | Buy → Buy | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.6% | +0.3% | +2.5% | +0.9% |
| Feb 17 | Stifel | Maintains | Hold → Hold | — | $17.03 | $17.07 | +0.2% | +4.1% | -0.3% | -0.1% | +1.6% | +0.3% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $16.58 | $16.22 | -2.2% | +1.3% | +1.9% | +1.6% | -0.6% | -0.5% |
| Dec 2 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $16.56 | $17.63 | +6.5% | +3.0% | -0.5% | -0.9% | +0.1% | -1.5% |
| Nov 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.69 | $15.58 | -0.7% | -0.6% | -3.8% | +0.7% | -3.2% | -0.4% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $15.69 | $15.58 | -0.7% | -0.6% | -3.8% | +0.7% | -3.2% | -0.4% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.14 | $15.21 | +0.5% | -1.3% | +2.1% | -1.6% | +4.9% | -1.3% |
| Oct 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $15.14 | $15.21 | +0.5% | -1.3% | +2.1% | -1.6% | +4.9% | -1.3% |
| Oct 30 | Raymond James | Maintains | Outperform → Outperform | — | $15.47 | $15.31 | -1.0% | -2.1% | -1.3% | +2.1% | -1.6% | +4.9% |
| Oct 30 | JP Morgan | Maintains | Neutral → Neutral | — | $15.47 | $15.31 | -1.0% | -2.1% | -1.3% | +2.1% | -1.6% | +4.9% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.47 | $15.31 | -1.0% | -2.1% | -1.3% | +2.1% | -1.6% | +4.9% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $15.47 | $15.31 | -1.0% | -2.1% | -1.3% | +2.1% | -1.6% | +4.9% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.89 | $14.81 | -0.5% | -1.5% | +0.3% | -2.0% | -0.7% | +3.9% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.63 | $13.58 | -0.4% | -1.0% | +1.6% | +5.2% | -2.3% | -2.2% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.71 | $13.55 | -1.2% | -0.6% | -1.0% | +1.6% | +5.2% | -2.3% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.71 | $13.55 | -1.2% | -0.6% | -1.0% | +1.6% | +5.2% | -2.3% |
| Jul 9 | Citigroup | Maintains | Neutral → Neutral | — | $14.00 | $13.92 | -0.6% | +0.4% | +1.1% | -2.3% | -1.4% | +0.2% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $13.81 | $13.85 | +0.3% | +1.4% | +0.4% | +1.1% | -2.3% | -1.4% |
| Jun 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $11.70 | $11.65 | -0.4% | +2.4% | +5.0% | -0.6% | -0.6% | -0.9% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.37 | $11.19 | -1.6% | -4.1% | +4.6% | +0.9% | -2.0% | +5.5% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.59 | $11.65 | +0.5% | -0.8% | -1.1% | -4.1% | +4.6% | +0.9% |
| May 1 | Citigroup | Maintains | Neutral → Neutral | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.8% | -1.1% | -4.1% | +4.6% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.8% | -1.1% | -4.1% | +4.6% |
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.8% | -1.1% | -4.1% | +4.6% |
| Apr 24 | Needham | Maintains | Hold → Hold | — | $12.74 | $13.37 | +4.9% | +9.0% | -1.2% | -0.5% | +0.4% | -15.7% |
| Apr 4 | RBC Capital | Maintains | Outperform → Outperform | — | $12.99 | $12.79 | -1.5% | -6.8% | -2.0% | -7.3% | +13.9% | -9.7% |
| Apr 3 | Stifel | Maintains | Hold → Hold | — | $14.35 | $13.90 | -3.1% | -9.5% | -6.8% | -2.0% | -7.3% | +13.9% |
| Mar 28 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $15.00 | $14.66 | -2.3% | -5.8% | +2.6% | -2.8% | +1.8% | -9.5% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.89 | $15.77 | -0.8% | -0.9% | +0.4% | +1.0% | -0.7% | -0.4% |
| Feb 20 | BofA Securities | Maintains | Underperform → Underperform | — | $16.30 | $16.04 | -1.6% | -2.5% | -0.9% | +0.4% | +1.0% | -0.7% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $16.30 | $16.04 | -1.6% | -2.5% | -0.9% | +0.4% | +1.0% | -0.7% |
| Feb 20 | Needham | Maintains | Hold → Hold | — | $16.30 | $16.04 | -1.6% | -2.5% | -0.9% | +0.4% | +1.0% | -0.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.41 | $16.35 | -0.4% | -0.4% | -0.3% | -2.5% | -0.9% | +0.4% |
| Jan 29 | Stifel | Maintains | Hold → Hold | — | $17.41 | $17.06 | -2.0% | +2.7% | -1.3% | -1.7% | +0.6% | +0.3% |
| Jan 29 | RBC Capital | Maintains | Outperform → Outperform | — | $17.41 | $17.06 | -2.0% | +2.7% | -1.3% | -1.7% | +0.6% | +0.3% |
| Jan 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.27 | $17.04 | -1.3% | +1.0% | -0.5% | -1.0% | -0.6% | -1.3% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.16 | $18.41 | +1.4% | +2.5% | -0.1% | -0.3% | +1.6% | -3.2% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $20.65 | $18.15 | -12.1% | -12.1% | +2.5% | -0.1% | -0.3% | +1.6% |
| Dec 2 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $19.82 | $19.25 | -2.9% | -1.8% | +1.0% | +0.4% | +0.9% | +0.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.44 | $20.49 | +0.2% | -0.8% | +1.1% | -3.1% | -0.3% | +0.1% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $20.44 | $20.49 | +0.2% | -0.8% | +1.1% | -3.1% | -0.3% | +0.1% |
| Oct 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $20.44 | $20.49 | +0.2% | -0.8% | +1.1% | -3.1% | -0.3% | +0.1% |
| Oct 22 | RBC Capital | Maintains | Outperform → Outperform | — | $20.68 | $20.45 | -1.1% | -1.6% | -1.3% | +0.5% | +1.4% | -0.4% |
| Oct 15 | Evercore ISI | Upgrade | In Line → Outperform | — | $20.87 | $21.33 | +2.2% | -0.6% | +0.1% | +0.8% | -1.4% | +0.2% |
No insider trades available.
8-K
Bausch + Lomb Corporation -- 8-K Filing
Bausch + Lomb delivered strong quarterly growth driven by dry eye treatments like MIEBO and XIIDRA, plus premium contact lenses and intraocular lenses, supporting management's strategy of sustainable expansion.
Apr 29
8-K
Unknown — 8-K Filing
Blco's phase 1/2 data showing 97% of patients eliminated eye drop dependency suggests strong commercial potential for its implantable device, making the $172.5M IPO attractive for investors seeking ophthalmology innovation exposure.
Mar 26
8-K
Bausch + Lomb Corporation -- 8-K Filing
Bausch + Lomb demonstrated improved operational efficiency in Q4 with EBITDA margin expansion, signaling management confidence in executing its three-year growth strategy.
Feb 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Oaktree Capital Management Lp | 6,765,478 | $108M | — | Mar 2026 |
| 2 | Icahn Carl C | 3,500,000 | $56M | — | Mar 2026 |
| 3 | D.e. Shaw & Co | 3,151,167 | $50M | Added | Mar 2026 |
| 4 | Davidson Kempner Capital Management Lp | 2,199,172 | $35M | New | Mar 2026 |
| 5 | Glenview Capital Management | 1,910,496 | $30M | New | Mar 2026 |
| 6 | Morgan Stanley | 1,426,534 | $24M | Reduced | Dec 2025 |
| 7 | Nomura Holdings Inc | 1,256,181 | $20M | — | Mar 2026 |
| 8 | Arrowstreet Capital, Limited Partnership | 982,062 | $16M | Reduced | Mar 2026 |
| 9 | Clark Estates Inc/ny | 825,000 | $14M | Reduced | Dec 2025 |
| 10 | Citadel Advisors Llc | 705,221 | $11M | Reduced | Mar 2026 |
| 11 | Clearline Capital Lp | 701,967 | $11M | Reduced | Mar 2026 |
| 12 | Gordonmd Global Investments Lp | 573,472 | $9M | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 453,179 | $7M | Added | Mar 2026 |
| 14 | Woodline Partners Lp | 386,876 | $6M | Reduced | Mar 2026 |
| 15 | Tudor Investment Corp | 376,446 | $6M | New | Mar 2026 |
| 16 | Millennium Management | 303,163 | $5M | Added | Mar 2026 |
| 17 | Point72 Asset Management | 283,138 | $5M | Added | Mar 2026 |
| 18 | Hrt Financial Lp | 224,700 | $4M | Added | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 165,829 | $3M | Added | Mar 2026 |
| 20 | Jane Street Group, Llc | 130,251 | $2M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$5.28B
Enterprise Value
$10.07B
P/E (TTM)
-24.12x
Forward P/E
18.87x
PEG Ratio
-1.26x
P/B
0.81x
P/S
1.01x
P/FCF
-80.03x
EV/EBITDA
15.51x
Shares Out
353.8M
Financials (TTM)
Revenue
$5.21B
Net Income
-$219.0M
EBITDA
$649.0M
Free Cash Flow
-$66.0M
Op Cash Flow
$283.0M
EPS Basic
$-1.02
EPS Diluted
$-0.62
EPS Forward
$0.79
Gross Margin
55.9%
Op Margin
5.9%
Net Margin
-4.2%
Balance Sheet
Total Assets
$14.02B
Total Liab.
$7.50B
Total Equity
$6.52B
Cash
$383.0M
LT Debt
$5.17B
Book Value/Sh
$18.43
Debt/Equity
0.83x
Current Ratio
1.55
Quick Ratio
1.04
Returns & Growth
ROE
-3.4%
ROA
-1.6%
ROIC
1.3%
Rev Growth YoY
+6.5%
EPS Growth YoY
-13.3%
Price Returns
2W
-3.8%
1M
-1.6%
3M
-14.5%
6M
-3.3%
12M
+36.4%
Technicals
52W High
$18.60
52W Low
$11.73
50d MA
$15.82
200d MA
$16.14
RSI (14)
41.70
ATR (14)
$0.38
Beta
0.65
Avg Volume
478K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$19.00
High
$21.00
Low
$16.00
Median
$20.00
Data updated apr 24, 2026 9:57pm
· Source: financialmodelingprep.com